Thus, the JAK inhibitor Ruxolitinib not only effectively suppresses the JAK-STAT3 signaling pathway within tumors, inhibiting both tumor metastasis and angiogenesis, but also significantly activates the tumor immune microenvironment, facilitating a transition from a “cold” to a “hot” immune landscape. This evidence concerns the gene STAT3 and neoplasm.